Core Idea

Transient senescent fibroblasts create a pericellular matrix‑bound PDGF‑AA gradient through high‑affinity binding to heparan sulfate proteoglycans (HSPGs). This gradient directs the spatial recruitment and differentiation of progenitor fibroblasts during wound healing. Chronic senescent cells lose HSPG‑bound PDGF‑AA due to upregulated heparanase activity, releasing soluble PDGF‑AA that drives diffuse, pro‑fibrotic signaling. Senolytic ablation removes both gradients, impairing organized repair while failing to distinguish the pathological soluble pool.

Mechanistic Insight

We propose that the switch from matrix‑bound to soluble PDGF‑AA is controlled by the senescence‑associated heparanase (HPSE) transcript, which is low in acute senescence but elevated in persistent senescence via NF‑κB‑dependent transcription. Bound PDGF‑AA presents a steep, tissue‑restricted cue that activates PDGFRα on migrating fibroblasts in a haptotactic fashion, promoting orderly matrix deposition. Soluble PDGF‑AA, by contrast, stimulates proliferation without directional guidance, leading to hyperplasia and excess collagen.

Testable Predictions

1. In acute wound models, senescent fibroblasts will show colocalization of PDGF‑AA with HSPG core proteins (e.g., syndecan‑1) and low HPSE expression; genetic or pharmacologic inhibition of HPSE will preserve the bound gradient and accelerate closure even when senolytics are administered.
2. In aged or diabetic mice with chronic senescent accumulations, HPSE will be upregulated, PDGF‑AA will be predominantly soluble, and exogenous HPSE inhibition will restore matrix‑bound PDGF‑AA, reduce fibrosis, and improve regenerative outcomes without clearing senescent cells.
3. Fluorescence recovery after photobleaching (FRAP) of labeled PDGF‑AA in wound tissue will reveal reduced mobility (high matrix binding) in young wounded tissue versus increased mobility in old wounded tissue; senolytic treatment will abolish both populations, resulting in uniformly low PDGF‑AA signal and delayed repair.

Experimental Approach

• Use p16‑3MR mice to label senescent cells; administer navitoclax (senolytic) or vehicle after standardized excisional wound.
• Quantify PDGF‑AA/HSPG colocalization via immunofluorescence and proximity ligation assay at 24h, 72h, and 7d.
• Measure HPSE mRNA and activity (fluorometric assay) in FACS‑sorted p16^+ fibroblasts.
• Apply heparanase inhibitor (PI‑88) or CRISPR‑Cas9 HPSE knockout in senescent cells to test rescue of bound PDGF‑AA and healing kinetics.
• Assess wound closure rate, histological fibrosis (Masson’s trichrome), and fibroblast trajectory tracking via intravital microscopy.

Potential Impact

If validated, this hypothesis reframes senolytics from blunt eliminators to precision tools that should spare—or even enhance—the matrix‑bound SASP fraction while targeting the soluble, pathogenic arm. It suggests combinatorial therapies (senolytic + heparanase inhibitor) could preserve the chaperone function of senescent cells during acute injury while mitigating their chronic deleterious effects.